"Checkpoint therapy" trang 1 - tải miễn phí từ tailieunhanh
Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme
7    94    1
Evaluation of the safety and immunological effects of Bacillus Calmette–Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: A case report

Evaluation of the safety and immunological effects of Bacillus Calmette–Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: A case report
7    21    1
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
12    54    1
Prevalence of immune-related adverse events and anti-tumor efcacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Prevalence of immune-related adverse events and anti-tumor efcacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
9    10    1
A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy

A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy
5    76    1
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
16    37    1
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
18    74    1
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study
9    29    1
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study
6    1    1
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%
12    1    1
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
10    1    1
Total serum N‑glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Total serum N‑glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
12    6    1
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients

TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
11    4    1
Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
14    1    1
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer
10    19    1
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: A case report

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: A case report
8    22    1
Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
10    52    0
CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model

CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model
12    56    0
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
10    74    0
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)
9    85    0